IndustryCompany release

OXB confirms manufacturing deal with Aura Biosciences for bel-sar Phase 3 and commercial supply

OXB · Tue 17 Nov 2026

The UK cell and gene therapy CDMO will support late-stage development and manufacture of Aura's virus-like drug conjugate for ocular cancers, with potential commercial supply in view.

OXB, the UK-based cell and gene therapy contract development and manufacturing organisation (CDMO), confirmed on 17 November 2026 that it has a manufacturing and supply partnership with Aura Biosciences.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release: OXB ↗

Article written by VigiEye from the official source (OXB). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →